Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01652157 · ClinicalTrials.gov registry record
Long-term Study in US Cystic Fibrosis Patients Receiving Digestive Enzyme Supplements to Assess Narrowing of the Large Intestine Causing Adverse Intestinal Symptoms (Fibrosing Colonopathy)
A clinical trial, sponsored by AbbVie.
- Terminated
- Registry status
- 17
- Enrollment target
NCT01652157 is a clinical trial that was terminated before completion, run by AbbVie. The registered enrollment target is 17 participants.
The verdict
NCT01652157 was terminated before completion, sponsored by AbbVie.
- TERMINATED
- Registry status
- 17 participants
- Enrollment target
Study Summary
This is a long-term study in cystic fibrosis patients who are participating in the Cystic Fibrosis Patient Registry to assess the occurrence and risk factors for a rare bowel disorder called fibrosing colonopathy (narrowing of the large intestine). Patients will be followed at their regular clinical care visits over a 10-year period and approached if they develop symptoms of fibrosing colonopathy for collection and use of further detailed information.
Interventions
- BIOLOGICAL ULTRESA
- BIOLOGICAL PANCREAZE
- BIOLOGICAL CREON
- BIOLOGICAL ZENPEP
- BIOLOGICAL other non-sponsor pancreatic enzyme replacement therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2012-07-31 |
| Est. Completion | 2020-04-08 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01652157
The ClinicalTrials.gov registry entry for NCT01652157 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which ULTRESA is the first listed.
NCT01652157 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01652157 about?
NCT01652157 is a clinical study titled "Long-term Study in US Cystic Fibrosis Patients Receiving Digestive Enzyme Supplements to Assess Narrowing of the Large Intestine Causing Adverse Intestinal Symptoms (Fibrosing Colonopathy)". This is a long-term study in cystic fibrosis patients who are participating in the Cystic Fibrosis Patient Registry to assess the occurrence and risk factors for a rare bowel disorder called fibrosing colonopathy (narrowing of the large intestine). Patients will be followed at their regular clinical...
What is the current status of trial NCT01652157?
This trial is currently terminated. The enrollment target is 17 participants. The study started on 2012-07-31. Estimated completion is 2020-04-08.
What interventions are being tested in trial NCT01652157?
The interventions under investigation include: ULTRESA (BIOLOGICAL), PANCREAZE (BIOLOGICAL), CREON (BIOLOGICAL), ZENPEP (BIOLOGICAL), other non-sponsor pancreatic enzyme replacement therapy (BIOLOGICAL).
Who is sponsoring clinical trial NCT01652157?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.